Tesamorelin

Localised redness, swelling, or itching at the injection site typically resolves within hours to days. Rotate injection sites to minimise recurrence. Apply ice if needed for comfort. Ensure proper injection technique and allow solution to reach room temperature before injection.

GH-induced fluid retention can compress the median nerve in the wrist, causing pain, numbness, or tingling in the hand. Reported in approximately 5–10% of tesamorelin users in clinical trials. Symptoms typically appear after 4–12 weeks of therapy. Manage with wrist splinting, NSAIDs, or dose reduction. Discontinue if symptoms are severe or progressive. Resolves within weeks of stopping therapy.

GH-induced fluid retention and metabolic changes can cause joint pain, particularly in the knees, hips, and shoulders. Usually mild and self-limiting. Manage with NSAIDs, stretching, and adequate hydration. Typically resolves within 4–8 weeks as the body adapts.

Muscle soreness or mild weakness may occur early in therapy, likely due to metabolic shifts and increased protein turnover. Usually resolves within 2–4 weeks. Ensure adequate protein intake and hydration.

GH stimulates sodium and water retention, potentially causing mild swelling in the hands, feet, or face. More common in patients with pre-existing hypertension or renal impairment. Manage with sodium restriction and adequate hydration. Typically mild and self-limiting. Monitor blood pressure regularly.

GH has anti-insulin effects and can transiently elevate fasting glucose or impair glucose tolerance, particularly in patients with pre-existing insulin resistance or diabetes. Monitor fasting glucose and HbA1c at baseline and during therapy. Usually mild and reversible. Tesamorelin's visceral fat reduction may improve insulin sensitivity over time, offsetting acute GH-induced effects.

Mild to moderate headaches reported in approximately 5–8% of users, possibly related to fluid retention or metabolic changes. Usually self-limiting. Manage with analgesics and hydration. Discontinue if severe or persistent.

Mild nausea, bloating, or changes in appetite may occur early in therapy. Usually transient and resolves within 1–2 weeks. Take with food if tolerated; ensure adequate hydration.

GH can increase blood pressure through fluid retention and increased cardiac output. Monitor blood pressure regularly, especially in patients with pre-existing hypertension. Manage with sodium restriction, weight loss, and antihypertensive medication if needed. Discontinue if blood pressure becomes uncontrolled.

GH can affect thyroid function and increase the risk of autoimmune thyroiditis in susceptible individuals. Monitor TSH and free T4 at baseline and annually during therapy. Manage with levothyroxine if hypothyroidism develops. More common in patients with pre-existing thyroid disease or autoimmune conditions.

GH-induced changes in sex hormone metabolism or increased aromatisation of androgens to oestrogen may rarely cause breast tissue growth in males. Usually mild and reversible. Discontinue if bothersome or progressive.

Theoretical concern with long-term GH elevation, though clinical evidence in tesamorelin trials is reassuring. Tesamorelin is contraindicated in patients with active malignancy or a history of malignancy within 5 years. Monitor for signs of malignancy during therapy. Discuss risk–benefit ratio with your healthcare provider, especially if you have a personal or family history of cancer.

Chronic peptide therapy can trigger antibody formation, potentially reducing efficacy over time. Reported in <5% of tesamorelin users in clinical trials. If efficacy wanes after initial improvement, antibody testing may be warranted. Discontinuation and rechallenge after a washout period may restore responsiveness.